Key Points:
- Teva signs $400 million strategic funding deal with Blackstone Life Sciences
- Funds to support Phase 3 development of duvakitug for ulcerative colitis and Crohn’s disease
- Blackstone eligible for milestones and royalties on global sales
- TEVA shares trading at $32.28 with a $37.02B market cap
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced Tuesday that its U.S. affiliate has entered into a $400 million strategic funding agreement with Blackstone Life Sciences to support the continued clinical development of duvakitug, an investigational treatment for inflammatory bowel disease (IBD).
The funding will be provided over four years and is designed to advance duvakitug through ongoing and future development programs. Under the agreement, Blackstone Life Sciences will be eligible for regulatory and commercial milestone payments, along with low single-digit royalties on worldwide sales of the drug, subject to approval and customary conditions.
Strengthening the Pipeline Under “Pivot to Growth”
Teva executives described the transaction as part of the company’s broader “Pivot to Growth” strategy aimed at accelerating innovation while maintaining financial discipline.
Evan Lippman, Executive Vice President of Business Development at Teva, said the partnership reflects the company’s commitment to capital-efficient dealmaking to advance its pipeline without straining its balance sheet.
The agreement allows Teva to share development risk while preserving long-term commercial participation in what it views as a high-potential asset.
Duvakitug Targets Large Unmet Need in IBD
Duvakitug is a human monoclonal antibody targeting TL1A, a pathway believed to amplify inflammation and drive fibrosis in inflammatory bowel disease. The drug is currently in Phase 3 clinical trials for ulcerative colitis (UC) and Crohn’s disease (CD).
IBD affects approximately 4.9 million people globally and is characterized by chronic inflammation of the gastrointestinal tract. The condition often involves recurring cycles of relapse and remission, with symptoms including persistent diarrhea, abdominal pain, rectal bleeding, and weight loss. There is currently no cure, and treatment focuses on inducing and maintaining remission.
Teva previously announced in 2023 that it is co-developing and, subject to regulatory approval, plans to co-commercialize duvakitug with Sanofi under a separate agreement. The companies recently reported Phase 2b maintenance data demonstrating durable and clinically meaningful efficacy in both UC and CD.
If approved by the U.S. Food and Drug Administration, Teva would owe Blackstone a milestone payment under the new agreement. The safety and efficacy of duvakitug have not yet been reviewed by regulatory authorities.
Market Reaction and Stock Performance
Shares of Teva were trading at $32.28 as of Tuesday, giving the company a market capitalization of approximately $37.02 billion. The stock has traded within a 52-week range of $12.47 to $37.35 and carries a price-to-earnings ratio of 26.52. Trading volume stood at 9.39 million shares.
Investors appear to view the structured financing arrangement as a strategic move that supports pipeline advancement without immediate shareholder dilution.
Expanding Innovation Footprint
Blackstone Life Sciences, which manages approximately $15 billion in assets, focuses on partnering with biopharmaceutical companies to accelerate the development of promising medicines and medical technologies. The firm’s leadership expressed confidence in duvakitug’s potential to become a leading therapy in a large and growing treatment category.
For Teva, the transaction underscores its effort to evolve beyond its legacy generics business and strengthen its innovative biopharmaceutical portfolio, particularly in immunology and specialty care.
As late-stage trials progress, duvakitug represents a potentially meaningful growth driver for Teva, particularly if Phase 3 data confirm earlier results and regulatory approval follows.
